The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Aduro Biotech (I); Astellas Pharma; AstraZeneca (I); Bayer; Celgene (I); Celsion; cipla; Exelixis; Genentech; Genentech (I); IntegraGen; Jennerex; Lilly/ImClone; MedImmune; Novartis; Pharmacyclics (I); Roche; Roche (I); Sanofi (I); Silenseed (I); Vicus Therapeutics; Vicus Therapeutics (I)
Research Funding - Abbott Laboratories (Inst); Amgen (Inst); Bayer (Inst); Exelixis (Inst); Genentech (Inst); Lilly/ImClone (Inst); Momenta Pharmaceuticals (Inst); Myriad Genetics (Inst); Novartis (Inst); OncoMed (Inst); Polaris (Inst); Roche (Inst); Sanofi (Inst); Vicus Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris
 
Ann-Lii Cheng
Consulting or Advisory Role - Daiichi Sankyo; Eisai; Exelixis
 
Tim Meyer
Consulting or Advisory Role - Exelixis
 
Anthony B. El-Khoueiry
Consulting or Advisory Role - Exelixis
 
Masafumi Ikeda
Consulting or Advisory Role - Exelixis
 
Hoo Geun Chun
Consulting or Advisory Role - Exelixis
Research Funding - Exelixis
 
Junji Furuse
Honoraria - Bayer; Chugai Pharma; Eisai; GlaxoSmithKline; Lilly; Taiho Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Fujifilm; Kyowa Hakko Kirin; Zeria Pharmaceutical
Speakers' Bureau - Chugai Pharma; Lilly; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Jennifer J. Knox
Research Funding - Bayer; Bristol-Myers Squibb; Novartis; Pfizer
 
Takuji Okusaka
Honoraria - Bayer; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Chugai Pharma; Dainippon Sumitomo Pharma; Lilly; NanoCarrier; Nippon Boehringer Ingelheim; Nobelpharma; Novartis; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Research Funding - AstraZeneca; Bayer; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly; Merck Serono; Nippon Boehringer Ingelheim; Novartis; OncoTherapy Science; Ono Pharmaceutical; Otsuka; Pfizer; Sceti Medical Labo; Siemens; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Jerry Ping
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
Travel, Accommodations, Expenses - Exelixis
 
Anne E. Borgman-Hagey
Employment - Exelixis
 
Robin Kate Kelley
Consulting or Advisory Role - Acceleron Pharma (Inst); Exelixis (Inst); Lilly (Inst)
Research Funding - Celgene (Inst); Exelixis (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Regeneron (Inst)